Amphastar Pharmaceuticals (AMPH) pipeline
TrialRedline tracks 2 clinical trials sponsored by Amphastar Pharmaceuticals, Inc.: 2 Phase 2 / 3.
Company identity checked against sources
Which trial dates moved later?
Amphastar Pharmaceuticals clinical trials we track
Check company identity sourcePhase 2 / 3 2 trials
Drugs in these trials
Names as written in the registry records.
Participant count type changed
Before: Estimated. After: Actual.
Enrollment · participant count changed
Before: 60 participants (planned). After: 62 participants (actual).
Completion date type changed
Before: Estimated. After: Actual.
Primary completion date changed
Before: Jun 2026. After: 22 Jun 2026.
Recruitment status changed
Before: Recruiting. After: Completed.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration from time 0 to 12 hours post-dose, AUCIA(0-12h) Measure: Maximum Serum Human Insulin Concentration, CHImax Measure: Area Under the Curve (AUC) of Human Insulin Serum Concentration from time 0 to 12 hours post-dose, AUCHI(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate from time 0 to 12 hours post-dose, AUCG(0-12h). After: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration From Time 0 to 12 Hours Post-dose, AUCIA(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate From Time 0 to 12 Hours Post-dose, AUCG(0-12h).